Punekar YS - Search Results

1

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.

Lindsay J, Punekar YS, Morris J, Chung-Faye G. Lindsay J, et al. Among authors: punekar ys. Aliment Pharmacol Ther. 2008 Jul;28(1):76-87. doi: 10.1111/j.1365-2036.2008.03709.x. Epub 2008 Apr 11. Aliment Pharmacol Ther. 2008. PMID: 18410558 Free article.

2

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.

Tsai HH, Punekar YS, Morris J, Fortun P. Tsai HH, et al. Among authors: punekar ys. Aliment Pharmacol Ther. 2008 Nov 15;28(10):1230-9. doi: 10.1111/j.1365-2036.2008.03839.x. Epub 2008 Aug 24. Aliment Pharmacol Ther. 2008. PMID: 18729845 Free article.

3

Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease.

Punekar YS, Sunderland T, Hawkins N, Lindsay J. Punekar YS, et al. Value Health. 2010 Mar-Apr;13(2):188-95. doi: 10.1111/j.1524-4733.2009.00658.x. Epub 2009 Oct 26. Value Health. 2010. PMID: 19883407 Free article. Clinical Trial.

4

Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.

Cummins E, Asseburg C, Punekar YS, Shore E, Morris J, Briggs A, Fenwick E. Cummins E, et al. Among authors: punekar ys. Value Health. 2011 Jan;14(1):15-23. doi: 10.1016/j.jval.2010.10.016. Value Health. 2011. PMID: 21211482 Free article.

5

Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.

Punekar YS, Hawkins N. Punekar YS, et al. Eur J Health Econ. 2010 Feb;11(1):67-76. doi: 10.1007/s10198-009-0199-5. Epub 2009 Oct 21. Eur J Health Econ. 2010. PMID: 19844750

6

Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.

Cummins E, Asseburg C, Prasad M, Buchanan J, Punekar YS. Cummins E, et al. Among authors: punekar ys. Eur J Health Econ. 2012 Dec;13(6):801-9. doi: 10.1007/s10198-011-0335-x. Epub 2011 Jul 1. Eur J Health Econ. 2012. PMID: 21720868

7

Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.

Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS. Tremblay G, et al. Among authors: punekar ys. Value Health Reg Issues. 2018 Sep;16:74-80. doi: 10.1016/j.vhri.2018.08.001. Epub 2018 Oct 5. Value Health Reg Issues. 2018. PMID: 30296624 Free article.

8

Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.

Punekar YS, Landis SH, Wurst K, Le H. Punekar YS, et al. Respir Res. 2015 Nov 16;16:141. doi: 10.1186/s12931-015-0295-2. Respir Res. 2015. PMID: 26572740 Free PMC article.

9

Cost-Effectiveness Analysis of Umeclidinium Bromide Compared to Tiotropium Bromide for Symptomatic Patients with COPD in the UK.

Ismaila A, Roberts G, Punekar YS, O'Leary M. Ismaila A, et al. Among authors: punekar ys. Value Health. 2014 Nov;17(7):A595. doi: 10.1016/j.jval.2014.08.2052. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202044 Free article. No abstract available.

10

Cost Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Combination Therapy Among Symptomatic COPD Patients.

Punekar YS, Roberts G, Ismaila A, O'Leary M. Punekar YS, et al. Value Health. 2014 Nov;17(7):A595. doi: 10.1016/j.jval.2014.08.2053. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202045 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters